New Alzheimer’s research from UVA Health suggests that enhanced light sensitivity may contribute to “sundowning” – the worsening of symptoms late in the day – and spur sleep disruptions thought to contribute to the disease’s progression.
Inventiva secures up to $380m for MASH treatment lanifibranor – Pharmaceutical Technology
The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in
October 14, 2024